Welcome to Miguel Prudêncio's website

Miguel Prudêncio completed his PhD by the University of East Anglia in 2000, followed by a post-doctoral period at the University of Leiden. In 2005, he initiated his research careeer in the field of malaria, at Instituto de Medicina Molecular, where  he became an independent Group Leader in 2013, heading the Prudêncio lab. He is Associate Professor of the Faculdade de Medicina da Universidade de Lisboa since March 2019, and completed his Habilitation to this Faculty in January 2023. Miguel’s research focuses on Plasmodium liver stages and their potential for anti-malarial intervention. His interests include unveiling novel aspects of the biology of Plasmodium infection, identifying drugs with antiplasmodial activity, establishing new experimental methodologies to study the malaria parasite, investigating the reciprocal impact of concurrent infections with Plasmodium and other infectious agents, and developing a new strategy for malaria vaccination. Miguel is the author of over 150 scientific articles, has earned several scientific and innovation prizes, and is an inventor of several patents. He is a founding member the iMM spin-off company RoPlaVac. He was involved in setting up iMM’s Task Force for SARS-CoV-2 diagnostics and has a keen interest on COVID-19 vaccination.